Universe Pharmaceuticals Inc - Asset Resilience Ratio
Universe Pharmaceuticals Inc (UPC) has an Asset Resilience Ratio of 5.11% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Universe Pharmaceuticals Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2023)
This chart shows how Universe Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See UPC net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Universe Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Universe Pharmaceuticals Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.53 Million | 5.11% |
| Total Liquid Assets | $2.53 Million | 5.11% |
Asset Resilience Insights
- Limited Liquidity: Universe Pharmaceuticals Inc maintains only 5.11% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Universe Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Universe Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 1.96% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 8.47% |
Annual Asset Resilience Ratio for Universe Pharmaceuticals Inc (2020–2023)
The table below shows the annual Asset Resilience Ratio data for Universe Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-09-30 | 24.81% | $13.22 Million | $53.29 Million | +2.72pp |
| 2022-09-30 | 22.08% | $13.15 Million | $59.54 Million | +2.52pp |
| 2021-09-30 | 19.57% | $13.73 Million | $70.14 Million | -- |
| 2020-09-30 | 0.00% | $0.00 | $28.80 Million | -- |
About Universe Pharmaceuticals Inc
Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. It also provides guben yanling, shenrong … Read more